Ahmed A Othman
Overview
Explore the profile of Ahmed A Othman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
2449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Younis I, Wang F, Othman A
J Clin Pharmacol
. 2024 Feb;
64(6):713-718.
PMID: 38346862
This work aimed to assess the feasibility of using population pharmacokinetics (popPK) to generate virtual healthy control groups in organ impairment studies. Data from 11 organ impairment studies containing 18...
12.
Weber E, Younis I, Wang L, Xiao D, Barchuk W, Othman A
Clin Pharmacol Drug Dev
. 2024 Feb;
13(6):677-687.
PMID: 38346861
Cilofexor is a nonsteroidal farnesoid X receptor agonist being developed in combination with firsocostat/semaglutide for the treatment of nonalcoholic steatohepatitis. This phase 1 study evaluated the effects of food and...
13.
Younis I, Hsueh C, Nelson C, Billin A, Yue M, Xiao D, et al.
J Clin Pharmacol
. 2023 May;
63(9):1017-1025.
PMID: 37128693
Cilofexor is a nonsteroidal farnesoid X receptor agonist in clinical development for treatment of nonalcoholic steatohepatitis. This work characterized the pharmacokinetics, pharmacodynamics, safety, and tolerability of cilofexor in participants with...
14.
Younis I, Weber E, Nelson C, Kirby B, Shen G, Xiao D, et al.
Clin Pharmacokinet
. 2023 Mar;
62(4):609-621.
PMID: 36906733
Background And Objective: Cilofexor is a selective farnesoid X receptor (FXR) agonist in development for the treatment of nonalcoholic steatohepatitis and primary sclerosing cholangitis. Our objective was to evaluate potential...
15.
Tolcher A, Gordon M, Mahoney K, Seto A, Zavodovskaya M, Hsueh C, et al.
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36746510
Background: Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions. This Phase 1 study (NCT03954704) evaluated...
16.
Weber E, Younis I, Nelson C, Ding D, Qin A, Xiao D, et al.
J Clin Pharmacol
. 2023 Jan;
63(5):560-568.
PMID: 36700458
Firsocostat, a liver-targeted acetyl-coenzyme A carboxylase inhibitor, and cilofexor, a nonsteroidal farnesoid X receptor agonist, are being developed in combination for treatment of nonalcoholic steatohepatitis. This phase 1 study evaluated...
17.
Younis I, Kirby B, Billin A, Xiao D, Song Q, Watkins T, et al.
Clin Transl Sci
. 2022 Dec;
16(3):536-547.
PMID: 36573450
Cilofexor is a nonsteroidal farnesoid X receptor (FXR) agonist being evaluated for treatment of nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). This work characterized the pharmacokinetics, pharmacodynamic, safety, and...
18.
Dauki A, Hsueh C, Cherala G, Othman A
Clin Pharmacol Ther
. 2022 Jun;
112(3):453-455.
PMID: 35687738
No abstract available.
19.
Othman A, Elgharably H, Vargo P, Ayyat K, Bakaeen F, Johnston D, et al.
Innovations (Phila)
. 2022 May;
17(3):201-208.
PMID: 35604783
Patients with thoracic aortic disease commonly present with concomitant multisegment pathology. We describe the patient population, analyze outcomes, and define the patient selection strategy for valve-preserving aortic root reimplantation (VPARR)...
20.
Cherala G, Nelson C, Guo Y, Mathur A, Tarnowski T, Othman A
Clin Transl Sci
. 2022 Mar;
15(6):1492-1499.
PMID: 35266297
Tirabrutinib (TIRA), a potent and nonreversible oral Bruton tyrosine kinase inhibitor, is evaluated for treatment of certain hematological malignancies and inflammatory diseases. A drug-drug interaction study to evaluate the effect...